RE:RE:RE:RE:RE:RE:So if deal falls through Look at it this way. ARLZ was looking to double their revenue from 2015 to 2016. TRX did that by itself more or less in the last year without having to wait for FDA approvals etc etc. A 100% increase in revenue still translates to your bottom line stock price whether you're talking about shares that cost a buck vs 10.
I know I'd be much richer today if TRX hadn't gone down this road. Still voting no. My hope is we get a press release that cancels the whole deal. I'll endure the ensuing market tantrum for a few weeks, if we didn't just already see it. When Q1 numbers are released in 2016, all would be forgotten, if not way before then. I don't need a tiny piece of a mega-corp to make money; I just need decent financial returns - which we were getting. I'm starting to think this deal is more in Harris'/Langille's self interest than the interest of TRX shareholders.
By the way, if you haven't got your proxy control ID yet, you can call your brokeridge and they can obtain it for you. At least that's what RBC told me.